Indian journal of ophthalmology · 2025
Clinical outcomes of cyclophosphamide therapy in relentless placoid choroiditis: A descriptive case series.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pedroza-Seres Miguel, Rodríguez-López Carlos E
Аннотация
PURPOSE: To describe the clinical presentation and visual outcomes of relentless placoid choroiditis (RPC) in four patients treated with intravenous cyclophosphamide, a treatment not extensively studied in this condition.
BACKGROUND: RPC is a rare and recently described ocular disease characterized by a prolonged and progressive clinical course, widespread lesions, and unknown etiology. There is no consensus on its treatment, and the use of cyclophosphamide in RPC has not been extensively studied.
CASE PRESENTATION: Four RPC patients treated with intravenous cyclophosphamide showed significant visual improvement (mean best-corrected visual acuity [BCVA] improved from 20/125 to 20/32) with minimal side effects.
CONCLUSION: This case series demonstrates favorable outcomes with intravenous cyclophosphamide in RPC, supporting its potential as a safe, effective, and cost-efficient treatment option.
BACKGROUND: RPC is a rare and recently described ocular disease characterized by a prolonged and progressive clinical course, widespread lesions, and unknown etiology. There is no consensus on its treatment, and the use of cyclophosphamide in RPC has not been extensively studied.
CASE PRESENTATION: Four RPC patients treated with intravenous cyclophosphamide showed significant visual improvement (mean best-corrected visual acuity [BCVA] improved from 20/125 to 20/32) with minimal side effects.
CONCLUSION: This case series demonstrates favorable outcomes with intravenous cyclophosphamide in RPC, supporting its potential as a safe, effective, and cost-efficient treatment option.